Highlights Newsletter 1
This newsletter presents you the following key sessions:
1. Podcast with Dr. Jeff Sharman about the 6-year follow-up results of the ELEVATE-TN trial evaluating acalabrutinib
treatment in CLL patients
2. Subcutaneous daratumumab plus VRd significantly improves PFS in patients with newly-diagnosed, transplant-
eligible multiple myeloma
3. Promising results of combination therapy with ibrutinib and venetoclax in relapsed or refractory mantle cell
lymphoma
4. Correlation between MRD-positivity and benefit of allogeneic transplant in NPM1-mutated AML, regardless of
FLT3 ITD